Potential for interactions between caspofungin and nelfinavir or rifampin. - Wikidata - wikimedia - TriplyDB

Potential for interactions between caspofungin and nelfinavir or rifampin.

Potential for interactions between caspofungin and nelfinavir or rifampin.

http://www.wikidata.org/entity/Q40288945

about

Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams Comparison of echinocandin antifungals Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.Human pharmacogenomic variations and their implications for antifungal efficacy.Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.Drug-drug interactions of antifungal agents and implications for patient care.The safety of anidulafungin.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.The echinocandins.Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis The pharmacology and clinical use of caspofungin.The use of caspofungin in HIV-infected individuals.A comparative evaluation of properties and clinical efficacy of the echinocandins.Antifungal agents--clinical pharmacokinetics and drug interactions.Rifampin combination therapy for nonmycobacterial infections.Interactions between antifungal and antiretroviral agents.Caspofungin: when and how? The microbiologist's view.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Antifungal therapy in children: an update.Antifungal agents in current pediatric practice.Invasive fungal infections in the ICU: how to approach, how to treat.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Impact of special patient populations on the pharmacokinetics of echinocandins.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment.In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation.Pharmacology of Systemic Antifungal Agents Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins

P2860

Q24631021-C8E185CB-8443-4107-95AC-281E9CC6F10E Q28273738-3D132B1D-8EE2-4E93-B986-1C15A7FF25B8 Q34932330-69272E94-AE0A-4062-BD27-58C273DA7D35 Q35070838-01118149-B69A-4A68-A6A9-013DA3267137 Q35666527-86EF3576-4BBE-4B5B-A4E8-A5FB787273B9 Q35959489-4CB4E61E-D02F-46B6-B4E3-9B371996E3F8 Q36176371-977B558F-4B2D-4CB8-A8AF-BF6FC90F9073 Q36271648-E9685569-7E77-49F1-958E-DE4F150CF60F Q36283721-0916FDC7-01AF-49C1-AA47-E51A6B99D638 Q36624970-0DC50689-588C-4B71-A809-B5B85E03E1A5 Q36626518-F01FF1F1-7AAA-482A-8227-0C5E1E6DE29A Q36742397-A93C16F5-DBBA-481A-A07D-12E370BE0545 Q36757591-FD002D7F-A825-4268-AE5B-DE002E445E6A Q36788428-EA846922-8683-4FC4-9699-C884ECFFCCAF Q36821383-F6C61D70-0A02-4735-8423-1D058E1D0E0D Q36895839-84BD0514-188B-476B-B0D3-C78E7E2910C4 Q37159568-A7D0273C-4133-48EE-B9D2-1EB699638428 Q37672039-730B906E-C3B5-4995-97E5-3A9C4260AE53 Q37719545-B758CA43-3166-426D-A3D1-EFAAB05B3751 Q37888750-FDA8567E-76B4-4E6D-83E9-1DE7C6DBBCC6 Q37904672-5A3B8E2D-A2A9-42B2-9F33-7BDBC4A428F2 Q38015090-57103CE3-D07B-4F17-AFB9-2248E8223A34 Q38101520-02827B73-85FC-4BBB-863D-DB4107FF9D5E Q38180287-17D9BF6E-DD14-4386-A1EE-82DA3DEAE8BD Q38284468-723CA831-ABFC-4178-AAD9-2B6D24442334 Q38462784-823B0F25-A1F0-4DEB-BB8D-6E38B5258983 Q38586680-D93D13DA-A2E2-4401-B34D-3C543C412E50 Q39701953-1DF12BD8-D051-4035-87D7-69F1E22018D8 Q42257734-D6CA1228-92F7-4283-9880-4CFF500EB87E Q43169846-383CEE16-28A5-4E90-A7D1-CB3A56279D87 Q46807629-B6432C37-95DD-41CF-BFA3-C66691E42C8E Q48301397-CAE219AE-1A31-42CE-BE51-5BE86F745D17 Q54957028-40FF2CC2-1D9F-4BCF-AF45-F2B413B17DB7 Q57533011-21D5F930-AADB-4B47-8F33-714BB844066E Q57746174-21A03F74-EB13-419E-AF90-6638D7B9D139

P2860

Potential for interactions between caspofungin and nelfinavir or rifampin.

http://www.wikidata.org/entity/Q40288945

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Potential for interactions between caspofungin and nelfinavir or rifampin.

@en

type

label

Potential for interactions between caspofungin and nelfinavir or rifampin.

@en

prefLabel

Potential for interactions between caspofungin and nelfinavir or rifampin.

@en

P1433

Q40288945-7C8DD953-0FDE-4339-95F9-17D006ED5AC3

P1476

Q40288945-C098B452-86C9-4896-A849-FF0FF1B858CF

P2093

Q40288945-0EA53EC7-DB90-4859-A384-313BFE4CB3D6

Q40288945-19A25CE2-7D81-4412-A7C5-228239A1330F

Q40288945-1FFB39E4-E080-48EA-9EBF-749441A44B13

Q40288945-2AEDC2F6-BB21-4771-A1D0-BFE1EE6B080D

Q40288945-5A722F16-B5F3-4906-9329-0620DA8E36A3

Q40288945-89A0612E-1C87-4176-B28C-27C8A22E4F68

Q40288945-969E1E66-ABFA-41A4-86FB-10298EB14610

Q40288945-9950BA5E-4E56-4523-B808-D1FD866FBC86

Q40288945-A708ABE4-6CAF-4B00-80E1-6C2BC91060D6

Q40288945-D049D847-835D-4081-BB33-2FAB048EABC8

P2860

Q40288945-09DCD722-FCBF-4669-9FF9-9ACA033C7AB2

Q40288945-196467D8-C03B-433E-8B37-C1265008788F

Q40288945-2A381533-C71E-4538-9E2D-EE66E2A10611

Q40288945-84B92A5A-88AF-4F89-AD8F-C2B407191431

Q40288945-86177D88-3119-47A3-9679-08C4EF70AAB3

Q40288945-89E2AB4B-AE31-47FE-98ED-C773FFFA02B9

Q40288945-9B84FEBF-443D-44AD-AEE9-1A3690512395

Q40288945-AA84EC3C-E901-428F-801A-D0DCBF84791B

Q40288945-B3FCF1D7-41BB-47FA-A304-7509E3A41584

Q40288945-BC955168-E587-47A3-91D2-BF066EBEBC72

P304

Q40288945-D94B7955-9FA3-4D0F-B404-2C5CFB79D70D

P31

Q40288945-1CE371BA-0CA3-41B7-B7AA-72B3474EECAE

P356

Q40288945-C781A615-E3F4-4F2F-8526-11181DFC86B9

P407

Q40288945-BAFE40B3-0F4F-4B5F-B608-A7F22C4A988C

P433

Q40288945-96247B7A-3D97-4B33-B730-96EC3EE3DFF8

P478

Q40288945-96E2087D-4440-46A8-A5C5-571D68B1E181

P50

Q40288945-A6A15700-77F3-4C9B-98C8-862E4BA6359B

P577

Q40288945-8F720C42-03ED-4E72-9FFE-BB5B90E8B455

P5875

Q40288945-AF6162E0-DD54-4AAF-B637-B33B4F63491E

P698

Q40288945-82F99B1B-8D17-4DA4-A02E-D488BE4916A4

P932

Q40288945-87C0B87E-E65E-4F13-BC9C-C8F6C15353CB

P356

AAC.48.11.4306-4314.2004

P1433

Antimicrobial Agents and Chemotherapy

P1476

Potential for interactions between caspofungin and nelfinavir or rifampin.

@en

P2093

Amanda Freeman

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Migoya

http://www.w3.org/2001/XMLSchema#string

Gregory A Winchell

http://www.w3.org/2001/XMLSchema#string

Howard Greenberg

http://www.w3.org/2001/XMLSchema#string

Julie A Stone

http://www.w3.org/2001/XMLSchema#string

Kalyan Ghosh

http://www.w3.org/2001/XMLSchema#string

Kenneth C Lasseter

http://www.w3.org/2001/XMLSchema#string

Lisa Hickey

http://www.w3.org/2001/XMLSchema#string

Paul J Deutsch

http://www.w3.org/2001/XMLSchema#string

Rajesh Desai

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species

Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives.

Safety and tolerability of caspofungin acetate in the treatment of fungal infections.

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.

P304

4306-4314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.48.11.4306-4314.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Walter K. Kraft

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8212090

http://www.w3.org/2001/XMLSchema#string

P698

15504857

http://www.w3.org/2001/XMLSchema#string

P932

525392

http://www.w3.org/2001/XMLSchema#string